CSF samples from patients with non-MYC-amplified MB (n = 3), ependymoma (n = 1), low grade glioma (n = 1), craniopharyngioma (n = 1) and a patient with a suspected pituitary apoplexy without malignancy (n = 1) were used as negative controls and revealed values of 1.1; 1.7; 0.6; 1.8; 1.5; 1.6; and 2.1, respectively (Figure S2). This evidence concerns the gene MYC and central nervous system cancer.